Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback